PFIZER INC Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure
PFIZER INC (PFE) reported Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure of $890.00 million for the 3-month period ending 2017-04-02, per its 10-Q filed 2017-05-11.
Discontinued › Notes
us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure · last filed 2017-05-11
- PFIZER INC concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2017-04-02 was $890.00M.
- PFIZER INC concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2011-04-03 was $3.10B.
- PFIZER INC concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2010-12-31 was $900.00M.
- PFIZER INC concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2010-10-03 was $100.00M.
- PFIZER INC concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2016 was $1.20B.
- PFIZER INC concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2010 was $2.70B.
| Period end | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 3 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 6 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 9 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 12 month |
|---|---|---|---|---|
| 2017-04-02 | $890.00M 10-Q · filed 2017-05-11 | |||
| 2016-12-31 | $1.20B 10-K · filed 2017-02-23 | |||
| 2011-04-03 | $3.10B 10-Q · filed 2011-05-12 | $4.00B derived: sum of 2 quarters · filed 2011-05-12 | $4.10B derived: sum of 3 quarters · filed 2011-05-12 | |
| 2010-12-31 | $900.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $1.00B derived: sum of 2 quarters · filed 2011-02-28 | $2.70B 10-K · filed 2011-02-28 | |
| 2010-10-03 | $100.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-12 | $1.80B 10-Q · filed 2010-11-12 | ||
| 2010-07-04 | $1.70B 10-Q · filed 2010-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |